Treatment guidelines in psoriatic arthritis

Rheumatology (Oxford). 2020 Mar 1;59(Suppl 1):i37-i46. doi: 10.1093/rheumatology/kez383.

Abstract

Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal and skin disease. The treatment of PsA has changed substantially over the past 10 years. Clinical practice guidelines are developed to help busy clinicians rapidly integrate evolving knowledge of therapeutic management into practice. In this review, we compare PsA treatment recommendations or guidelines developed by one national organization [ACR and National Psoriasis Foundation (NPF) in 2018], one regional organization (EULAR in 2015), and one international organization (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis in 2015). We examine the development of guidelines in PsA more broadly and examine similarities and differences in the three sets of recommendations.

Keywords: outcomes; psoriatic arthritis; therapy; treat-to-target; treatment guidelines.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Psoriatic / pathology
  • Biological Factors / therapeutic use*
  • Biomarkers / analysis
  • Comorbidity
  • Disease Management
  • Humans
  • Molecular Targeted Therapy / methods*
  • Practice Guidelines as Topic
  • Rheumatology / standards
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Biological Factors
  • Biomarkers